The PPAR-γ agonist, pioglitazone, was initially used as an anti-diabetes medication; however, it has recently been used for treating inflammatory bowel disease, such as UC (Lewis et al., 2001, 2008). This evidence concerns the gene PPARG and inflammatory bowel disease.